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Abstract 
Objective There is a global call for formulations, which are better suited for 
children of different age categories and in a variety of settings. One key 
public health area of interest is age-appropriate paediatric antibiotics. We 
aimed to identify clinically relevant paediatric formulations of antibiotics 
listed on pertinent formularies that were not on the WHO Essential 
Medicines List for Children (EMLc). 
Methods We compared four medicines lists versus the EMLc and 
contrasted paediatric antibiotic formulations in relation to administration 
routes, dosage forms and/or drug strengths. The additional formulations 
on comparator lists that differed from the EMLc formulations were 
evaluated for their added clinical values and costs. 
Results The analysis was based on 26 EMLc antibiotics. Seven oral and two 
parenteral formulations were considered clinically relevant for paediatric 
use. Frequently quoted benefits of oral formulations included: filling the 
gap of unmet therapeutic needs in certain age/weight groups 
(phenoxymethylpenicillin and metronidazole oral liquids, and nitrofurantoin 
capsules), and simplified administration and supply advantages (amoxicillin 
dispersible tablets, clyndamycin capsules, cloxacillin tablets, and 
sulfamethoxazole+trimethoprim tablets). Lower doses of ampicillin and 
cefazolin powder for injection could simplify the dosing in newborns and 
infants, reduce the risk of medical errors, and decrease the waste of 
medicines, but may target only narrow age/weight groups. 
Conclusions The identified additional formulations of paediatric antibiotics 
on comparator lists may offer clinical benefits for low-resource settings, 
including simplified administration and increased dosing accuracy. The 
complexity of both procuring and managing multiple strengths and 
formulations also needs to be considered. 
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